Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Brainstorm Cell Therapeutics Inc
BCLI | US
0.73
USD0.02
2.77%
BCLI | US
Loading StockChartView...
About Brainstorm Cell Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.73
Open
0.70
High
0.73
Low
0.63
Brainstorm Cell Therapeutics Inc. a biotechnology company engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company through its NurOwn proprietary cell therapy platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors modulate neuroinflammatory and neurodegenerative disease processes promote neuronal survival and enhance neurological function. It is developing NurOwn which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York New York.
View LessBCLI | US
Risk
110.5
Sharpe
-0.66
Luna's Score
52/100
Recommendation
Hold
Luna says (BCLI | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
90.6%1 month
110.5%3 months
92.4%6 months
76.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
65.82
Debt to equity
-0.27
Debt to assets
0.17
Ent. to EBITDA
-1.70
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-16.04M
MarketCap
3.88M
MarketCap(USD)
3.88M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.12K
Short ratio
5.98
Short perc.
2.48
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.22
Range1M
0.27
Range3M
0.27
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.32
Price X volume
26.64K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.70 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 65.82 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 92.36 | 72.80 | Riskier |
| Debt to Equity | -0.27 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 3.88M | 3.66B | Emerging |
